Biopharmaceuticals Companies

Latest Biopharmaceuticals Companies Update

Bristol Myers Squibb Acquires Turning Point Therapeutics: This USD 3.4 billion deal bolsters Bristol Myers Squibb's oncology pipeline with Turning Point's TP-5992, a promising drug candidate for solid tumors.

AbbVie Snaps Up Teneobio: This USD 1.6 billion acquisition strengthens AbbVie's immunology portfolio with Teneobio's TNX-102, a potential treatment for inflammatory bowel disease.

Regeneron Receives FDA Approval for Dupixent to Treat Eosinophilic Esophagitis: This expands the reach of Dupixent, a blockbuster drug already approved for asthma, eczema, and other allergic conditions.

AstraZeneca's Imfinzi Wins FDA Approval for Extensive-Stage Small Cell Lung Cancer: This marks a significant milestone in the treatment of this aggressive cancer, offering a new option for patients.

• Pfizer, Inc. (US)


• Amgen Inc. (US)


• Eli Lilly and Company (US)


• Hoffmann-La Roche Ltd (Switzerland)


• Johnson & Johnson (US)


• Gilead Sciences, Inc. (US)


• AstraZeneca (UK)


• Abbvie Inc. (US)


• Sanofi (France)


• Bristol-Myers Squibb Company (US)


• Sandoz International GmbH (Germany)


• Novo Nordisk A/S (Denmark)


• GlaxoSmithKline PLC (UK)


• Merck KGaA (Germany)


• Biocon (India)